Correlation Analysis Between Peripheral Blood PrPC Levels and Disease Severity and Prognosis in Patients With Acute Cerebral Infarction

The First Hospital of Jilin University79 enrolled

Overview

The primary objective of this observational study is to investigate alterations in PrPc levels in peripheral blood during acute cerebral infarction, as well as the correlation between these changes and both disease severity and prognosis. Additionally, it aims to explore the association between peripheral blood PrPc and T-cell-mediated inflammatory responses in acute cerebral infarction. Key research questions addressed include: how PrPc concentrations in peripheral blood change during acute cerebral infarction, and whether such variations correlate with clinical severity and patient outcomes. No interventions were administered in this study, and all patients received standard diagnostic and therapeutic care without disruption. Fasting venous blood samples were collected on the morning following hospital admission, and follow-up assessments using the modified Rankin Scale (mRS) were conducted at 90 days post-onset.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Acute Cerebral Infarction

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years Exclusion Criteria: * (1) patients who received intravenous thrombolysis or endovascular intervention; (2) patients with infectious diseases, autoimmune diseases, or those receiving immunosuppressive or immunomodulatory therapy; (3) patients with a history of cerebral infarction or intracerebral hemorrhage within the past year; (4) patients with severe hepatic or renal dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding three times the upper limit of normal, serum creatinine levels \>265 μmol/L, heart failure, or malignant tumors.

Outcomes

Primary Outcomes

3-month mRS

Functional outcomes were assessed at 3 months by trained medical personnel via telephone interviews using the modified Rankin Scale (mRS). Favorable outcomes were defined as no symptoms to mild disability (mRS 0-2), whereas unfavorable outcomes were defined as moderate disability to death (mRS 3-6).

Time frame: three months after the onset of the disease